Nan Fung Group Holdings’s KalVista Pharmaceuticals KALV Stock Holding History

Nan Fung Group Holdings’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-154,522	Closed	-$1.78M	–	26
2025 Q1	$1.78M	Hold	154,522	–	–	1.45%	22
2024 Q4	$1.31M	Hold	154,522	–	–	1.12%	23
2024 Q3	$1.79M	Sell	154,522 -64,755	-30%	-$814K	1.54%	21
2024 Q2	$2.58M	Hold	219,277	–	–	2.76%	13
2024 Q1	$2.6M	Sell	219,277 -85,000	-28%	-$1.13M	2.41%	12
2023 Q4	$3.73M	Buy	304,277 +69,704	+30%	+$634K	2.32%	10
2023 Q3	$2.26M	Buy	234,573 +29,853	+15%	+$305K	1.83%	11
2023 Q2	$1.84M	Buy	204,720 +126,000	+160%	+$1.16M	1.18%	17
2023 Q1	$619K	Hold	78,720	–	–	0.42%	29
2022 Q4	$532K	Hold	78,720	–	–	0.37%	27
2022 Q3	$1.14M	Hold	78,720	–	–	0.73%	18
2022 Q2	$775K	Hold	78,720	–	–	0.53%	22
2022 Q1	$1.16M	Hold	78,720	–	–	0.55%	24
2021 Q4	$1.04M	Hold	78,720	–	–	0.31%	27
2021 Q3	$1.37M	Hold	78,720	–	–	0.44%	19
2021 Q2	$1.89M	Buy	+78,720	New	+$2.06M	0.59%	17

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Nan Fung Group Holdings's KALV Position: Q2 2025 in Review

Nan Fung Group Holdings sold out of KalVista Pharmaceuticals (KALV) in Q2 2025, closing a stake of 154,522 shares — an estimated $1.78M sold.

Nan Fung Group Holdings first reported a position in KALV in Q2 2021 and held it in 16 quarters. The position peaked at $3.73M in Q4 2023. 139 funds tracked by Wall St. Rank hold KALV as of Q2 2025.

Nan Fung Group Holdings reported no remaining KalVista Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Nan Fung Group Holdings sold 154,522 KalVista Pharmaceuticals shares in Q2 2025, an estimated $1.78M.
Nan Fung Group Holdings first reported a position in KalVista Pharmaceuticals in Q2 2021 and held it in 16 quarters.
Nan Fung Group Holdings's KalVista Pharmaceuticals position peaked at $3.73M in Q4 2023.
139 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2025.

Based on Nan Fung Group Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.